Effect of valdecoxib pretreatment on pain and secondary hyperalgesia

A randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]

David Burns, Lindsay Hill, Michael Essandoh, Tomasz M. Jarzembowski, H. Gregg Schuler, Piotr Janicki

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Background: Induction of the COX-2 isoenzyme appears to play a major role in the genesis of central sensitization after nociceptive stimulation. This study aimed to investigate the efficacy of a single, oral dose of the specific COX-2 inhibitor-valdecoxib in attenuating the central sensitization - induced secondary hyperalgesia in a heat/capsaicin pain model in healthy volunteers. Methods: The study was a randomized, double blind, placebo controlled, crossover, single dose efficacy trial using 20 healthy volunteers. Two hours following placebo or 40 mg, PO valdecoxib, participants underwent skin sensitization with heat/capsaicin, as well as supra-threshold pain and re-kindling measurements according to an established, validated pain model. Subjects rated pain intensity and unpleasantness on a visual analog scale and the area of secondary hyperalgesia was serially mapped. Results: The area of secondary hyperalgesia produced after 40 mg of val decoxib was no different than that after placebo. Furthermore, there were no significantly relevant differences when volunteers were treated with valdecoxib or placebo in relation to either cold- or hot pain threshold or the intensity of pain after supra-threshold, thermal pain stimulation. Conclusion: We demonstrated that a single, oral dose of valdecoxib when does not attenuate secondary hyperalgesia induced by heat/capsaicin in a cutaneous sensitization pain model in healthy volunteers.

Original languageEnglish (US)
Article number3
JournalBMC Anesthesiology
Volume6
DOIs
StatePublished - Mar 10 2006

Fingerprint

Hyperalgesia
Healthy Volunteers
Randomized Controlled Trials
Pain Threshold
Capsaicin
Pain
Hot Temperature
Placebos
Central Nervous System Sensitization
Skin
Cyclooxygenase 2 Inhibitors
Visual Analog Scale
Isoenzymes
Volunteers
valdecoxib

All Science Journal Classification (ASJC) codes

  • Anesthesiology and Pain Medicine

Cite this

@article{0b3271f04d634b92bfd11a0230f7725e,
title = "Effect of valdecoxib pretreatment on pain and secondary hyperalgesia: A randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]",
abstract = "Background: Induction of the COX-2 isoenzyme appears to play a major role in the genesis of central sensitization after nociceptive stimulation. This study aimed to investigate the efficacy of a single, oral dose of the specific COX-2 inhibitor-valdecoxib in attenuating the central sensitization - induced secondary hyperalgesia in a heat/capsaicin pain model in healthy volunteers. Methods: The study was a randomized, double blind, placebo controlled, crossover, single dose efficacy trial using 20 healthy volunteers. Two hours following placebo or 40 mg, PO valdecoxib, participants underwent skin sensitization with heat/capsaicin, as well as supra-threshold pain and re-kindling measurements according to an established, validated pain model. Subjects rated pain intensity and unpleasantness on a visual analog scale and the area of secondary hyperalgesia was serially mapped. Results: The area of secondary hyperalgesia produced after 40 mg of val decoxib was no different than that after placebo. Furthermore, there were no significantly relevant differences when volunteers were treated with valdecoxib or placebo in relation to either cold- or hot pain threshold or the intensity of pain after supra-threshold, thermal pain stimulation. Conclusion: We demonstrated that a single, oral dose of valdecoxib when does not attenuate secondary hyperalgesia induced by heat/capsaicin in a cutaneous sensitization pain model in healthy volunteers.",
author = "David Burns and Lindsay Hill and Michael Essandoh and Jarzembowski, {Tomasz M.} and Schuler, {H. Gregg} and Piotr Janicki",
year = "2006",
month = "3",
day = "10",
doi = "10.1186/1471-2253-6-3",
language = "English (US)",
volume = "6",
journal = "BMC Anesthesiology",
issn = "1471-2253",
publisher = "BioMed Central",

}

Effect of valdecoxib pretreatment on pain and secondary hyperalgesia : A randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]. / Burns, David; Hill, Lindsay; Essandoh, Michael; Jarzembowski, Tomasz M.; Schuler, H. Gregg; Janicki, Piotr.

In: BMC Anesthesiology, Vol. 6, 3, 10.03.2006.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Effect of valdecoxib pretreatment on pain and secondary hyperalgesia

T2 - A randomized controlled trial in healthy volunteers [ISRCTN05282752, NCT00260325]

AU - Burns, David

AU - Hill, Lindsay

AU - Essandoh, Michael

AU - Jarzembowski, Tomasz M.

AU - Schuler, H. Gregg

AU - Janicki, Piotr

PY - 2006/3/10

Y1 - 2006/3/10

N2 - Background: Induction of the COX-2 isoenzyme appears to play a major role in the genesis of central sensitization after nociceptive stimulation. This study aimed to investigate the efficacy of a single, oral dose of the specific COX-2 inhibitor-valdecoxib in attenuating the central sensitization - induced secondary hyperalgesia in a heat/capsaicin pain model in healthy volunteers. Methods: The study was a randomized, double blind, placebo controlled, crossover, single dose efficacy trial using 20 healthy volunteers. Two hours following placebo or 40 mg, PO valdecoxib, participants underwent skin sensitization with heat/capsaicin, as well as supra-threshold pain and re-kindling measurements according to an established, validated pain model. Subjects rated pain intensity and unpleasantness on a visual analog scale and the area of secondary hyperalgesia was serially mapped. Results: The area of secondary hyperalgesia produced after 40 mg of val decoxib was no different than that after placebo. Furthermore, there were no significantly relevant differences when volunteers were treated with valdecoxib or placebo in relation to either cold- or hot pain threshold or the intensity of pain after supra-threshold, thermal pain stimulation. Conclusion: We demonstrated that a single, oral dose of valdecoxib when does not attenuate secondary hyperalgesia induced by heat/capsaicin in a cutaneous sensitization pain model in healthy volunteers.

AB - Background: Induction of the COX-2 isoenzyme appears to play a major role in the genesis of central sensitization after nociceptive stimulation. This study aimed to investigate the efficacy of a single, oral dose of the specific COX-2 inhibitor-valdecoxib in attenuating the central sensitization - induced secondary hyperalgesia in a heat/capsaicin pain model in healthy volunteers. Methods: The study was a randomized, double blind, placebo controlled, crossover, single dose efficacy trial using 20 healthy volunteers. Two hours following placebo or 40 mg, PO valdecoxib, participants underwent skin sensitization with heat/capsaicin, as well as supra-threshold pain and re-kindling measurements according to an established, validated pain model. Subjects rated pain intensity and unpleasantness on a visual analog scale and the area of secondary hyperalgesia was serially mapped. Results: The area of secondary hyperalgesia produced after 40 mg of val decoxib was no different than that after placebo. Furthermore, there were no significantly relevant differences when volunteers were treated with valdecoxib or placebo in relation to either cold- or hot pain threshold or the intensity of pain after supra-threshold, thermal pain stimulation. Conclusion: We demonstrated that a single, oral dose of valdecoxib when does not attenuate secondary hyperalgesia induced by heat/capsaicin in a cutaneous sensitization pain model in healthy volunteers.

UR - http://www.scopus.com/inward/record.url?scp=33645466575&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33645466575&partnerID=8YFLogxK

U2 - 10.1186/1471-2253-6-3

DO - 10.1186/1471-2253-6-3

M3 - Article

VL - 6

JO - BMC Anesthesiology

JF - BMC Anesthesiology

SN - 1471-2253

M1 - 3

ER -